Logo

BMS Signs a Five-Year Agreement with Insitro to Develop Therapies for ALS and Frontotemporal Dementia

Share this

BMS Signs a Five-Year Agreement with Insitro to Develop Therapies for ALS and Frontotemporal Dementia

Shots:

  • Insitro to receive $50M as up front- $20M as near-term operational milestones and is eligible to receive ~$2B+ as discovery- development- regulatory and commercial milestones along with royalties on sales of the therapies
  • BMS will lead the clinical development- regulatory submissions- and commercialization activities. Insitro will apply its insitro Human (ISH) platform- to create iPSC derived disease models for ALS and FTD
  • Insitro will apply ML-enabled therapeutics discovery capabilities to advance programs while BMS to get an option to select several targets identified by insitro to advance through clinical development and commercialization

 Ref: Businesswire | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions